Coya Therapeutics Inc. ISIN: US22407B1089 Forum: Aktien User: Solix

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

The ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being conducted at clinical sites in the United States and Canada Dosing of ALS patients has commenced in the ALSTARS Trial and signifies a key milestone for the Company. COYA 302, a combination of proprietary low-dose IL-2 and CTLA-4 Ig, is designed to enhance the number and function of regulatory T cells while suppressing the pro-inflammatory myeloid activity that drives ALS progression. COYA will receive a $4.2 million milestone payment from its strategic partner, Dr. Reddy’s Laboratories (DRL), for the achievement of this milestone

Interessant hier

👀

Läuft 👌

👀

💎🤣🚀

ℹ Coya ist ein klinisches Biotechnologieunternehmen, dass sich darauf konzentriert, proprietäre neue Therapien zur Verbesserung der Funktion von regulatorischen T-Zellen zu verbessern. Sie entwickeln derzeit eine Multi-Modalität Treg-Therapien für neurodegenerative, autoimmune und Stoffwechselerkrankungen.